Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

被引:1232
作者
Dvorak, HF
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
关键词
D O I
10.1200/JCO.2002.10.088
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor A (VEGF-A), the founding member of the vascular permeability factor (VPF)/VEGF family of proteins, is an important angiogenic cytokine with critical roles in tumor angiogenesis. This article reviews the literature with regard to VEGF-A's multiple functions, the mechanisms by which it induces angiogenesis, and its current and projected roles in clinical oncology. VEGF-A is a multifunctional cytokine that is widely expressed by tumor cells and that acts through receptors (VEGFR-1, VEGFR-2, and neuropilin) that are expressed on vascular endothelium and on some other cells. It increases microvascular permeability, induces endothelial cell migration and division, reprograms gene expression, promotes endothelial cell survival, prevents senescence, and induces angiogenesis. Recently, VEGF-A has also been shown to induce lymphangiogenesis. Measurements of circulating levels of VEGF-A may have value in estimating prognosis, and VEGF-A and its receptors are potential targets for therapy. Recognized as the single most important angiogenic cytokine, VEGF-A has a central role in tumor biology and will likely have an important role in future approaches designed to evaluate patient prognosis. It may also become an important target for cancer therapy. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:4368 / 4380
页数:13
相关论文
共 217 条
[1]   Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma [J].
Abdulrauf, SI ;
Edvardsen, K ;
Ho, KL ;
Yang, XY ;
Rock, JP ;
Rosenblum, ML .
JOURNAL OF NEUROSURGERY, 1998, 88 (03) :513-520
[2]  
Adams J, 2000, CANCER RES, V60, P2898
[3]   Advances in disease biology: Therapeutic implications [J].
Anderson, KC .
SEMINARS IN HEMATOLOGY, 2001, 38 (02) :6-10
[4]  
[Anonymous], 2002, Drugs R D, V3, P28
[5]   Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas [J].
Aoki, Y ;
Tosato, G .
LEUKEMIA & LYMPHOMA, 2001, 41 (3-4) :229-+
[6]  
Bachelder RE, 2001, CANCER RES, V61, P5736
[7]   Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology [J].
Banks, RE ;
Forbes, MA ;
Kinsey, SE ;
Stanley, A ;
Ingham, E ;
Walters, C ;
Selby, PJ .
BRITISH JOURNAL OF CANCER, 1998, 77 (06) :956-964
[8]   The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor [J].
Basu, S ;
Nagy, JA ;
Pal, S ;
Vasile, E ;
Eckelhoefer, IA ;
Bliss, VS ;
Manseau, EJ ;
Dasgupta, PS ;
Dvorak, HF ;
Mukhopadhyay, D .
NATURE MEDICINE, 2001, 7 (05) :569-574
[9]  
Bellamy WT, 1999, CANCER RES, V59, P728
[10]   Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal [J].
Benjamin, LE ;
Keshet, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) :8761-8766